Sensorion Aktie [WKN DE: A14SVV / ISIN: FR0012596468]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Sensorion SA

31.03.21		Sensorion Senior Management to Attend Four Conferences in April 2021 (Businesswire)
25.03.21		Sensorion Publishes Results of Extraordinary General Meeting Resolutions (Businesswire)
18.03.21		Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights (Businesswire)
12.03.21		Sensorion to Present at Two Conferences on March 16th 2021 (Businesswire)
19.02.21		Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021 (Businesswire)
17.02.21		Sensorion Announces That an Extraordinary General Meeting Will Be Held Behind Closed Doors on March 24, 2021 (Businesswire)
17.02.21		Sensorion : A Chardan Top Pick for 2021 (Businesswire)
15.02.21		Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments (Businesswire)
19.01.21		Sensorion Announces Preclinical Data Demonstrating SENS-401’s Potential to Preserve Residual Hearing After Cochlear Implantation (Businesswire)
07.01.21		Sensorion Announces Initiation of Coverage by Investment Banks Jefferies and Kempen With a "Buy” Recommendation (Businesswire)
05.01.21		Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss (Businesswire)
15.12.20		Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss (Businesswire)
20.11.20		Sensorion Hosting Key Opinion Leader Call with Dr. John Greinwald on Genetic Hearing Loss in Children on December 2, 2020 (Businesswire)
03.11.20		Sensorion Announces Attendance and a Presentation at Upcoming Conferences (Businesswire)
27.10.20		Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement (Businesswire)
15.10.20		Sensorion Obtains €3 Million Loans, Including €2 Million Guaranteed by the French Government (PGE) and €1 Million as RDI Loan Through Bpifrance (Businesswire)
01.10.20		Sensorion Announces Attendance and Presentations at Upcoming Conferences (Businesswire)
18.09.20		Sensorion beschafft rund 31 Millionen Euro (36,5 Millionen US-Dollar) durch eine überzeichnete Privatplatzierung bei US-amerikanischen und europäischen Investoren (Businesswire)
18.09.20		Sensorion beginnt Kapitalerhöhung durch beschleunigtes Bookbuilding-Verfahren (Businesswire)
18.09.20		Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors (Businesswire)
17.09.20		Sensorion Launches a Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
14.08.20		Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA (Businesswire)
29.07.20		Sensorion appoints five renowned experts to its Scientific Advisory Board (Businesswire)
20.07.20		Sensorion Will Present at the Bioprocessing Summit Europe Virtual Conference on July 21-23, 2020 (Businesswire)
16.07.20		Sensorion Hosting Key Opinion Leader Call with Dr. Michael Hoffer on Sudden Sensorineural Hearing Loss and SENS-401 as a Potential Treatment Option on July 23, 2020 (Businesswire)
06.07.20		Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board (Businesswire)
17.06.20		Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a "Buy” Recommendation (Businesswire)
09.06.20		Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program (Businesswire)
21.05.20		Sensorion Publishes Results of General Assembly Resolutions (Businesswire)
29.04.20		Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report (Businesswire)
24.04.20		Sensorion reschedules General Assembly to May 20 (Businesswire)
02.04.20		Sensorion Reports Full-year 2019 Financial Results and Business Update (Businesswire)
13.03.20		Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment (Businesswire)
19.02.20		Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer (Businesswire)
13.02.20		Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares (Businesswire)
10.02.20		Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares (Businesswire)
03.02.20		Sensorion to Attend and Present at LSX World Congress 2020 (Businesswire)
30.01.20		Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020 (Businesswire)
10.01.20		Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference (Businesswire)
23.12.19		Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 Trial for SENS-401 in Sudden Sensorineural Hearing Loss (Businesswire)
23.12.19		Sensorion Announces €5.6m Non-Dilutive Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss; French Ministry of Armed Forces to Participate in the Study (Businesswire)
02.12.19		Sensorion Announces Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy (Businesswire)
07.11.19		Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover (Businesswire)
31.10.19		Sensorion reports its 2019 first half results (Businesswire)
23.10.19		Sensorion Announces a Poster Presentation of New SENS-401 Preclinical Data at SFN 2019 in Chicago (Businesswire)
17.10.19		Sensorion Announces the Last Patient’s Last Visit in SENS-111 Phase 2 Clinical Trial (Businesswire)
17.09.19		Sensorion Announces Two Presentations at AAO-HNSF 2019 in New Orleans (Businesswire)
11.09.19		Sensorion Announces Three Presentations at IEB 2019 in Padua (Businesswire)
07.08.19		Sensorion Announces Appointment of John Furey, Former COO of Spark Therapeutics, as Independent Board Member (Businesswire)
31.07.19		Sensorion: Reporting of the General Assembly Appointment of Three New Directors (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin Kurs Prognose: Absturz auf 90.000 US-Dollar bereits diese Woche?

EQS-CMS: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Release of a capital market information

Trump stellt erneut US-Rolle bei Vereinten Nationen infrage

ams-OSRAM-Aktie schächelt: ams-OSRAM erhält EU-Freigabe für staatliche Förderung aus Österreich

Investieren in die Zukunft: Diese 5 Quantencomputing-Aktien sind vielversprechend

Bundestagswahl in Deutschland: Union laut Hochrechnungen klar vorn, FDP scheitert an Fünf-Prozent-Hürde - SPD verliert deutlich

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.02.2025 21:29
Kaufwert:	EUR
	Hinzufügen Speichern